How should I interpret a peripheral blood and bone marrow report in acute myeloid leukemia?

How to Interpret Peripheral Blood and Bone Marrow Reports in AML

Interpretation of AML reports requires systematic integration of morphology, immunophenotyping, cytogenetics, and molecular studies from both peripheral blood and bone marrow specimens, with bone marrow evaluation remaining the gold standard for diagnosis and response assessment 1.

Essential Components to Review

1. Morphologic Assessment

Start by reviewing the complete blood count (CBC) with differential and examining both peripheral blood and bone marrow smears 1:

• Blast percentage: AML diagnosis requires ≥20% blasts in blood or marrow (lower thresholds apply for certain genetic subtypes)
• Blast morphology: Note Auer rods (suggest myeloid lineage), cytoplasmic granulation, nuclear features
• Dysplastic features: Assess all three lineages for dysplasia
• Bone marrow cellularity: Hypercellular vs. hypocellular patterns
• Core biopsy architecture: Evaluate alongside aspirate smears; if aspirate is inadequate ("dry tap"), touch preparations from core biopsy become critical 1

Critical pitfall: Ensure the bone marrow sample is adequate and not hemodiluted—mast cell quantification can help identify hemodiluted samples (affects ~15% of cases) 2.

2. Immunophenotyping by Flow Cytometry

The flow cytometry panel must distinguish AML from acute lymphoblastic leukemia (ALL) and acute leukemia of ambiguous lineage 1:

• Myeloid markers: CD13, CD33, CD117, MPO
• Monocytic markers: CD14, CD64, CD11b
• Immaturity markers: CD34, HLA-DR, CD38
• Aberrant expression: Cross-lineage markers (CD7, CD19, CD56) help establish leukemia-associated immunophenotypes (LAIP) for future MRD monitoring

When peripheral blood can substitute: If peripheral blood contains ≥30% blasts, immunophenotyping can be performed on blood alone, though marker expression may differ quantitatively from bone marrow 3, 4. In AML specifically, markers like CD3, CD5, CD13, CD14, CD19, CD45, HLA-DR, and TdT show strong correlation between blood and marrow 4.

3. Cytogenetic Analysis (Karyotype)

Conventional karyotyping is mandatory and cannot be replaced by FISH or molecular testing 1:

• Favorable risk: t(8;21), inv(16)/t(16;16), t(15;17) (APL)
• Adverse risk: Complex karyotype (≥3 abnormalities), monosomal karyotype, -5/del(5q), -7/del(7q), inv(3)/t(3;3)
• Intermediate risk: Normal karyotype, other abnormalities

4. Molecular Genetic Testing

Perform targeted molecular testing for prognostic and therapeutic markers 1:

• Favorable: NPM1 mutation (without FLT3-ITD high allelic ratio), biallelic CEBPA mutations
• Adverse: FLT3-ITD (high allelic ratio), TP53 mutations, RUNX1 mutations, ASXL1 mutations
• Targetable: FLT3-ITD/TKD (midostaurin, gilteritinib), IDH1/IDH2 mutations (ivosidenib, enasidenib)

FISH and molecular testing complement but do not replace conventional cytogenetics 1.

Algorithmic Approach to Report Interpretation

Step 1: Confirm Diagnosis

• Verify blast percentage ≥20% (or presence of defining genetic abnormality)
• Confirm myeloid lineage by morphology and immunophenotype
• Rule out APL immediately (look for t(15;17), PML::RARA)

Step 2: Risk Stratification

• Integrate cytogenetic and molecular findings using ELN 2022 risk classification
• This determines intensity of therapy and transplant candidacy

Step 3: Identify Targetable Mutations

• FLT3, IDH1/2, TP53 status guides therapy selection
• Document baseline LAIP for future MRD monitoring

Step 4: Assess Clinical Context

Review clinical information that should accompany the pathology report 1:

• Age, sex, ethnicity
• Prior hematologic disorders or therapy-related exposure (chemotherapy, radiation)
• Recent growth factors or transfusions (can obscure findings)
• Family history of hematologic malignancies
• Physical exam findings: organomegaly, extramedullary disease, neurologic symptoms

Peripheral Blood vs. Bone Marrow: When Each Is Sufficient

For initial diagnosis: Bone marrow evaluation is strongly recommended for all suspected AML cases 1, 3. However, if peripheral blood contains sufficient blasts, diagnosis and ancillary studies can be performed on blood alone 1.

For response assessment: Bone marrow remains the standard for evaluating remission and measurable residual disease (MRD), though peripheral blood MRD monitoring shows promise 2, 5, 3. MRD positivity is less common in peripheral blood than bone marrow (concordance rate ~74%), with quantitative and qualitative differences in aberrant antigen expression 2.

For relapse monitoring: Peripheral blood may be adequate when blasts are circulating, offering less invasive serial monitoring 5, 3.

Common Pitfalls to Avoid

• Hemodiluted bone marrow samples: Lead to falsely low blast counts; use mast cell quantification as quality control 2
• Confounding factors: Recent growth factors, transfusions, or medications can mimic or obscure AML features 1
• Relying solely on peripheral blood: While feasible when blasts are abundant, bone marrow provides superior sensitivity for MRD detection 2, 3
• Skipping conventional cytogenetics: FISH and molecular panels do not capture all prognostically relevant abnormalities 1
• Inadequate immunophenotyping panel: Must be comprehensive enough to distinguish AML from ALL and ambiguous lineage leukemia 1

Correlation and Reporting

The same physician should ideally interpret both bone marrow aspirate and core biopsy, or interpretations should be explicitly correlated if performed by different pathologists 1. The final integrated report should synthesize morphology, immunophenotype, cytogenetics, and molecular findings into a coherent diagnosis with risk stratification.